Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute fo	r form 1449/	PTO		Complete if Known		
	INFORMATIO			Application Number	10/582,650	-	
	STATEMENT	BY APPLI	CANT	Filing Date	June 13, 2006		
	Date Submitted:	Sentember	21 2007	First Named Inventor	DOBROVOLNY, Petr		
Date Submitted: September 21, 2007				Art Unit	1625		
	(use as many s	heets as ne	cessary)	Examiner Name	Aulakh, Charanjit		
Sheet	1	of	3	Attorney Docket Number	078556-0143		

			U.S. PATENT DO	CUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines Where Relevant
Initials*	No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
	A1	US-3,894,029	07-08-1975	Winterfeldt et al.	
	A2	US-4,031,098	06-21-1977	Sugasawa	
	A3	US-4,399,276	07-13-1982	Yokovama et al.	
	A4	US-4,399,282	08-16-1983	Miyasaka et al.	*****
	A5	US-4,473,692	09-25-1984	Miyasaka et al.	
	A6	US-4,604,463	08-05-1986	Miyasaka et al.	
	A7	US-4,914,205	04-03-1990	Sawada et al.	
	A8	US-5,061,800	10-29-1991	Yaegashi et al.	
	A7	US-5,491,237	02-13-1996	Fang et al.	
	A9	US-5,602,141	02-11-1997	Bedeschi et al.	
	A10	US-5,734,056	03-31-1998	Burk et al.	
	A11	US-5,843,954	12-01-1998	Yaegashi et al.	
	A12	US-6,235,907	05-22-2001	Henegar et al.	
	A13	US-6,310,210	10-30-2001	Ogawa et al.	***************************************
	A14	US-6,403,569	06-11-2002	Achterrath	
	A15	US-6,444,820	09-03-2002	Henegar et al.	
	A16	US-6,743,918	06-01-2004	Yaegashi et al.	
	A17	US-6,794,370	09-21-2004	Achterrath	
	A18	US-7,126,000	10-24-2006	Ogawa et al.	
	A19	US-7,151,179	12-19-2006	Lin et al.	
	A20	US-2004/0235878	11-25-2004	Lin et al.	
	A21	US-2005/0272757	12-08-2005	Naidu	
	A22	US-2006/0199961	09-07-2006	Dobrovolny	
	_			+	

Examiner Cite Document Sited Document Name of Patentee or Applicant of Where Relevan	UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS							
MM-DD-YYYY Cited Document	Examiner Initials*	Cite No.1	Document Serial Number-Kind Code ² (if	Cited Document	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

Examiner Signature		Date Considered	
*EYAMINED: Initi	of reference considered whether as not elletten in in a seferance with MDED cod. D.	F - 0 1 1 1 1 1 1 1	

P 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.usplo.gov or MPEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 03/31/2007, OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.						_	
(Substitute fo	r form 1449/	РТО		Complete if Known		
l	INFORMATIO			Application Number	10/582,650	***************************************	
l	STATEMENT	BY APPLI	CANT	Filing Date	June 13, 2006		
	Date Submitted:	Sentember	21 2007	First Named Inventor	DOBROVOLNY, Petr		
				Art Unit	1625		
	(use as many si	heets as ne	cessary)	Examiner Name	Aulakh, Charanjit		
Sheet	2	of	3	Attorney Docket Number	078556-0143		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6			
	A23	EP74256	11-20-1986	Miyasaka et al.		T			
	A24	EP74770	03-23-1983	Miyasaka et al.		+			
	A25	EP88642	09-14-1983	Miyasaka et al.		+			
	A26	EP154583	09-11-1988	Funck et al.		1			
	A27	EP154584	02-03-1988	Pressaco et al.		_			
	A28	EP51289	04-09-1986	Gelert		_			
	A29	WO96/31513	10-10-1996	Henegar et al.		-			
	A30	WO2004/100897	11-25-2004	Lin et al.		_			
	A31	WO2005/019223	03-03-2005	Dobrovolny		1			
	A32	WO2005/058910	06-30-2005	Dobrovolny		_			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	A33	"Combination of Innotecan (CPT-11) and 5-Fluorouracil with an analysis of cellular determinants of drug activity," PAVILLARD et al., Biochemical Pharmacology, vol. 56: 1315-1322, 1998."	
	A34	"Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies," ARMAND, Jean-Pierre et al., Anti-Cancer Drugs 10 (Suppl. 1): S5-S12 (1999).	
	A35	"Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ("De Gramont" regimen) every 2 weeks in the treatment of colorectal cancer (CRC) after 5-FU failure," DUCREUX, M. et al., Abstract 823, Proc. of Amer. Soc. Clin. Oncol. 16:2344 (1997).	
	A36	"Phase I study of a weekly schedule of innotecan (CPT-11), high-dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer: Final results," VANHOEFER, U. et al., Abstract 779, Proc. of Amer. Soc. Clin, Oncol. 17:202a (1988).	
	A37	*Innotecan (CPT-11) in the treatment of gastrointestinal cancers,* NISHIYAMA, M., Japanese J. Chemotherapy 46(8):292-296 (1998).	
	A38	"CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer," SALTZ, L. et al., European J. Cancer 32A(Suppl. 3):S24-S31 (1996).	

Examiner Signature		Date Considered	
*EVALUNED, Initia	difference and dead to the second state of the		

*EXAMINET: Initial if reference considered, whether or not classion is in conformance with NFEP 600. Draw line through classion if no in conformance are do not considered. Include copy of this from with next communication to applicate. It applicants' unsuper classion designation number (probability). 25ee Kinds Codes of USEPTO Patent Documents at www.uspib.gov or MFEP 901.04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).4 For Japanese patent documents, his indication of the year of the religion of the Emperor must precede the sealing number of the patent document. St Mort document by the opportate symbols as indicated on the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 11.97 and 13.8. The information is required to obtain or reliant a benefit by the public which is to file (and by the USFTO to

process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFB.1.4. This collection is estimated to take 2 house, which is a livel give up of yer USF (1.0) process) and submitting the completed application from to the USF (1.0) to the completed application from to the USF (1.0) to the view of the completed application from to the USF (1.0) to the view of the completed application from to the USF (1.0) to the view of t

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control

	Substitute for form	1449/F	ото		Complete if Known		
	INFORMATION DI			Application Number	10/582,650		
	STATEMENT BY	APPLIC	CANT	Filing Date	June 13, 2006		
	Date Submitted: Sept	ember	21 2007	First Named Inventor	DOBROVOLNY, Petr		
				Art Unit	1625		
	(use as many sheets	as nec	cessary)	Examiner Name	Aulakh, Charanjit		
Sheet	3	of	3	Attorney Docket Number	078556-0143		

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	s* No.1 item (book, magazine, journal, señal, symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published.					
	A39	*Phase I/II study of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5-FU failure,* SEITZ, J.F. et al., Abstract 261, Annals of Oncology 9 (Suppl. 2)				
	A40	Phase I study of a weekly schedule of innotecan (CPT-11) in combination with high-dose folinic acid and 5-forcouracil as first line chemotherapy in patients with advanced colorectal cancer," VANHOEFER, U. et al., Abstract 967, Proc. of Amer. Soc. Clin. Oncol. 16:272 a (1997).				
	A41	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives. A-Ring-Substituted 7- Ethylcamptothecins and their Enig-Modified Water-Soluble Derivatives," YAEGASHI et al., Chemical & Pharmaceutical Bulletin. 04. 24, No. 12: 5218-2525 (1994.)				
	A42	*Chemical Modification of an Antitumor Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins,* SAWADA et al., Chemical & Pharmaceutical Bulletin. Vol. 39. No. 10: 2574-2580 (1991).				
	A43	Synthesis and Antitumor Activity of A-Ring or E-Lactone Modified Water-Soluble Prodrugs of 20(S)- Camptothecin, Including Development of Irinotecan Hydrochloride Trihydrate," SAWADA et al., Current Pharmaceutical Design. Vol. 1 No. 1: 113-132 (1995).				
	A44	Photodegradation reactions of CPT-II, a derivative of camptothecin. I: chemical structure of main degradation products in an aqueous solution," AKIMOTO et al., Drug Stability. Vol. 1 No. 2.: 118-122 (1996).				
	A45	*An Efficient Conversion of Camptothecin to 10-Hydroxycamptothecin, *WOOD et al., The Journal of Organic Chemistry, Vol. 60. No. 17: 5739-5740 (1995).				
	A46	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin," SAWADA et al., Chemical & Pharmaceutical Bulletin, Vol. 39. No. 6: 1446-1454 (1991).				
	A47	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7, 10- Disubstituted Camptothecins," SAWADA et al., Chemical & Pharmaceutical Bulletin, Vol. 39. No. 12: 3183- 3188 (1991).				

Examiner Signature	Date Considered	

"EXAMINET: Initial If reference considered, whether or not clatation is in conformance with MEEP 600. Draw live though clatation if on its nonformance and not considered, include copy of this form with next communication to applicant. If applicant's insuign catation designation number (optional) 2.5 ex Kirst Codes of USPTO Pasent Documents at www.uspto.gov or MEEP 901.04.3 Enter Office that issued the document, by the two-letter code (WEPO Standard ST3.) 4 For Japanese patent documents, the indication of the year of the region of the Emperor must precede the sensition untimes of the patent document. Styling of documents by the appropriate symbols as indicated on the document under WIPO Standard ST1.01 for ossible. 6 Applicant is to place a check mark here if English binguage Translation is attached.

This collection of Information is required to Ostion or relatar benefit by the public which is to file (and by the USPTO to

process) an application. Confidentiality is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including patienting, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual scale. Any comments on the amounted to the school of the part of the p